Five series of tetrahydrobenzothieno[2,3-d]pyrimidine and tetrahydrobenzothienotriazolopyrimidine derivatives have been synthesized namely: 4-(substituted amino)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidines 4a–d, 4-substituted (methylidenehydrazino)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidines 6a–c, 4-(3,5-disubstituted pyrazol-1-yl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine...

The arylidienes of spiro thiazolidines (5) containing α,β-unsaturated function have been used as component of Micheal addition with equimolar amount of 2-aminopyridine (6a) to give novel spiro [indole-3,2′-pyrido[1,2-a]thiazolo[5,4-e]pyrimidines] (7) in a single step under microwaves in presence of montmorillonite KSF as solid support. The new improved synthetic method for spiro [indole-3, 2′-t...

The incorporation in vivo of compounds labeled with N15 or Cl4 into the purines and pyrimidines of nucleic acid has been repeatedly demonstrated (e.g. (l-3)). W e wish to report observations on the incorporation of radioactive erotic acid in vitro into the pyrimidines of the nucleic acid of rat liver slices. It is believed that this procedure will readily permit the study of precursors of nucle...

Kinetic studies on the reactions of Y-aryl phenyl isothiocyanophosphates with substituted X-anilines and deuterated X-anilines were carried out in acetonitrile at 55.0 °C. The free-energy relationships with X in the nucleophiles were biphasic concave upwards with a break region between X = H and 4-Cl, giving unusual positive ρX and negative βX values with less basic anilines (X = 4-Cl and 3-Cl)...

silica-bonded n-propyldiethylenetriamine sulfamic acid (spdtsa) is employed as a recyclable heterogeneous solid acid catalyst for the synthesis of benzopyrano[2,3-d]pyrimidines  through one-pot condensation reaction of salicylaldehydes, malononitrile and secondary amines  at room temperature under solvent-free conditions. spdtsa showed much the same efficiency when used in consecutive reaction ...

The toxicology community should be aware that pharmaceutical companies are developing deuterated analogues of therapeutic agents, purported to have improved margins of safety and reduced potential for drug interactions, according to a recent report (1). According to the article in Nature, companies are " snapping up intellectual property rights " on many of the modified drugs. Earlier this year...